Acne Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Acne Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Acne Treatment Market

The acne treatment market size was valued at USD 11.09 billion in 2023, and the market is now projected to grow from USD 11.62 billion in 2024 to USD 17.48 billion by 2032, exhibiting a CAGR of 5.2% during the forecast period of 2024-2032.

The COVID-19 pandemic created significant opportunities on the acne treatment market growth as curbing coronavirus outbreak was prioritized. There has been a boom in the range of patient visits to hospitals and clinics as the regulations imposed by governments in their COVID-19 reaction have been relaxed. Besides, the general spike in the income of medicines that have been used to deal with acne is related to using medical face masks for an extended duration, which has increased the applicability of medicine throughout the pandemic as well as post-pandemic years.

The acne treatment market share globally has been contributed due to the rising acne prevalence globally. Skin disease occurs as a global pandemic due to its popularity and prevalence. Based on statistics from the American Academy of Dermatology, over 56 million people in the United States have acne problems now, as of 2022. In this regard, the fast-growing quantity of people availing of this service is a twin issue in both developing and developed countries.

Furthermore, there’s been a notable trend of growing clinical approval of drugs. The rising problem has been found among teenagers and other young generations, which has made manufacturers eyewitnesses to the demand for drugs for acne treatment at the highest level. The field of drug development strives to attain the goal of tackling acne appropriately and without any life-threatening side effects.

Comprehensive Analysis of Acne Treatment Market

The acne treatment market and healthcare industry are rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessment considering the dominant supply and demand forces that impact the healthcare industry. These segmentations are methodically segregated by types of products, distribution channel, route of administration, and age group. The distribution channel types include, retail & online pharmacies and hospital pharmacies. However, the route of administration is such as topical and oral.

The North American region is conducive to the global acne treatment market, leading to a recall of USD 5.45 billion owing to increasing prevalence of acne across the region. The region can boast such a trend due to the rising cystic acne incidence in the area and the overall rise of beauty consciousness among different population groups. Also, multiple aspects were involved including a substantial increase in patients who are under treatment, a high level of awareness on new treatments and presence of major international brands are factors that highly contributed to the compensation of demand for those products and this is why the region has the first place in the world.

The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include, ABBVIE INC. (Ireland), , GlaxoSmithKline Plc. (U.K.), Botanix Pharmaceuticals (Australia), GALDERMA (Switzerland), Johnson & Johnson Services, Bayer AG (Germany), Inc. (U.S.), Pfizer Inc. (U.S.), Bausch Health Companies Inc. (U.S.), and Teva Pharmaceutical Industries Ltd. (Israel) these market players provide a level-playing competitive landscape.

Glenmark Pharmaceuticals Ltd and Cosmo Pharmaceuticals NV signed the agreement on acne treatment with the ointment Winlevi on September 2023 for the pharmaceutical distribution as well as for a license agreement that covers the Europe and South Africa.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Yea 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 5.2% from 2024-2032

Unit Value (USD Billion)

Segmentation By Product

- Retinoids

- Antibiotics

- Isotretinoin

- Others

By Route of Administration

- Oral

- Topical

By Age Group

- 10 to 17 Years

- 18 to 44 Years

- 45 to 64 Years

- 65 Years & Above

By Distribution Channel

- Hospital Pharmacies

- Retail & Online Pharmacies

By Geography

- North America (By Product, By Route of Administration, By Age Group, By Distribution Channel, and By Country)

U.S. (By Product)

Canada (By Product)

- Europe (By Product, By Route of Administration, By Age Group, By Distribution Channel, and By Country)

U.K. (By Product)

Germany (By Product)

France (By Product)

Italy (By Product)

Spain (By Product)

Rest of Europe (By Product)

- Asia Pacific (By Product, By Route of Administration, By Age Group, By Distribution Channel, and By Country)

China (By Product)

Japan (By Product)

India (By Product)

Australia (By Product)

Southeast Asia (By Product)

Rest of Asia Pacific (By Product)

- Latin America (By Product, By Route of Administration, By Age Group, By Distribution Channel, and By Country)

Brazil (By Product)

Mexico (By Product)

Rest of Latin America (By Product)

- Middle East & Africa (By Product, By Route of Administration, By Age Group, By Distribution Channel, and By Country)

GCC (By Product)

South Africa (By Product)

Rest of MEA (By Product)